《大行報告》中金下調丘鈦科技(01478.HK)目標價至4元 評級「跑贏行業」
中金發表評級報告指,丘鈦科技(01478.HK)上半年收入按年下跌23%至54.8億元人民幣(下同),歸母淨利潤按年跌87%至0.21億元,低於盈警預告區間,亦低於中金預期。
中金表示,展望下半年,公司將今年32MP以上模組出貨佔比指引從35%提升至40%,反映對於高端產品結構的傾斜。中金表示,考慮到全球手機需求相對疲軟將對公司產能利用率形成短期壓力,將公司今年盈利預測下調63%至1.27億元,明年則下調34%至2.99億元。
該行將其目標價下調39.4%至4港元,維持其評級為「跑贏行業」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.